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Abstract
Background: An East African survey showed that among the few health facilities that measured adherence to
antiretroviral therapy, practices and definitions varied widely. We evaluated the feasibility of collecting routine data
to standardize adherence measurement using a draft set of indicators.
Methods: Targeting 20 facilities each in Ethiopia, Kenya, Rwanda, and Uganda, in each facility we interviewed up
to 30 patients, examined 100 patient records, and interviewed staff.
Results: In 78 facilities, we interviewed a total of 1,631 patients and reviewed 8,282 records. Difficulties in retrieving
records prevented data collection in two facilities. Overall, 94.2% of patients reported perfect adherence; dispensed
medicine covered 91.1% of days in a six month retrospective period; 13.7% of patients had a gap of more than 30
days in their dispensed medication; 75.8% of patients attended clinic on or before the date of their next
appointment; and 87.1% of patients attended within 3 days.
In each of the four countries, the facility-specific median indicators ranged from: 97%-100% for perfect self-reported
adherence, 90%-95% of days covered by dispensed medicines, 2%-19% of patients with treatment gaps of 30 days
or more, and 72%-91% of appointments attended on time. Individual facilities varied considerably.
The percentages of days covered by dispensed medicine, patients with more than 95% of days covered, and
patients with a gap of 30 days or more were all significantly correlated with the percentages of patients who
attended their appointments on time, within 3 days, or within 30 days of their appointment. Self reported recent
adherence in exit interviews was significantly correlated only with the percentage of patients who attended within
3 days of their appointment.
Conclusions: Field tests showed that data to measure adherence can be collected systematically from health
facilities in resource-poor settings. The clinical validity of these indicators is assessed in a companion article. Most
patients and facilities showed high levels of adherence; however, poor levels of performance in some facilities
provide a target for quality improvement efforts.
Background
Global, regional, and national health initiatives have
responded to the HIV/AIDS pandemic by introducing
antiretroviral therapy (ART) to ever-increasing num-
bers of affected patients. The success of ART relies on
life-long, high levels of medication adherence to maxi-
mize clinical effectiveness and to minimize the
potential population risks associated with the develop-
ment of drug resistance. Evidence for a goal of main-
taining adherence rates of 90% [1,2] to 95% [3] have
been presented, although recent evidence has ques-
tioned the validity of that standard [4,5]. Reviews of
over 50 years of research have shown that achieving
medication adherence rates of over 80% for treating a
range of chronic illnesses has been problematic, even
in resource-rich countries [6,7]. Achieving high rates
of adherence in resource poor settings is a serious
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monitored.
The ability to measure treatment adherence accurately
is critical to identifying adherence problems and
improving adherence practices. Common methods for
measuring adherence to antiretroviral (ARV) medica-
tions involve using patient self-reports [8-10]; pill counts
[11,12]; pharmacy dispensing data [7,13-15] and, primar-
ily in research settings, electronic medication monitors
[16-19]. Each method has strengths and limitations, but
individually, each method fails to capture important
dimensions of ARV treatment adherence [12,20-22]. All
methods produce measurements associated with clinical
outcomes in research settings; however, to our knowl-
edge, none of the approaches to measuring adherence
have been tested for feasibility and validity using routine
data from the array of current treatment program set-
tings in Africa.
Countries and global donors have agreed on the
importance of supporting and monitoring adherence
among patients on antiretroviral therapy [23], although
they have been unable to reach consensus on optimal
strategies for measuring or improving adherence at the
patient or system level [23,24]. The assessment reported
here was designed to investigate the feasibility of using
routine data collected in a systematic way in a wide vari-
ety of facilities to construct standardized indicators that
reflect the performance of facilities in maintaining their
patients on therapy. In a companion article, the validity
of these indicators is tested and reported [25].
In 2006, the International Network for the Rational
Use of Drugs Initiative on Adherence to Antiretrovirals
(INRUD-IAA), in collaboration with the national AIDS
control programs from Ethiopia, Kenya, Rwanda, Tanza-
nia, and Uganda, carried out a survey that assessed how
existing ART programs and health care facilities tracked
patient adherence and treatment defaulting [26]. ART
programs had started in Uganda as early as 1991, in
Rwanda 1999, Kenya 2001, Ethiopia 2003 and Tanzania
2004. However, the survey showed that many programs
and facilities had no processes in place to measure treat-
ment adherence or defaulting at either the patient or
program level, and among those facilities that did con-
duct measurements, definitions and data collection prac-
tices varied widely, although they routinely collected
useful data [26] .
Using these survey results along with measurement
approaches described in the adherence literature [11,12],
INRUD-IAA collaborators defined a draft set of core
indicators for monitoring adherence and attendance that
could be calculated from data routinely available in
ARV treatment clinics and developed standardized
methods to collect data and calculate indicators.
The draft adherence indicators and their data sources
include:
￿ Self-reported, short-term adherence: Percentage of
patients that report perfect adherence and the aver-
age percentage of doses of ARV medicine they
report having missed during the previous three days,
using data from interviews with patients exiting
from a clinic and from self-reported adherence data
recorded in clinical records.
￿ Dispensing-based long-term adherence: Percentage
of days covered by ARV medicines dispensed over
the last six months or a year and percentage of a
cohort of patients who had a gap of at least 30 days
between dispensing, assessed from pharmacy dispen-
sing records.
￿ Consistency of visit attendance: Percentage of
patients attending appointments on or before the
scheduled day and percentage attending within three
days after scheduled appointments, taken from clinic
appointment logs.
￿ Pill count-based medium-term adherence: Average
percentage of days patients took ARVs as expected
based on pill counts as noted in clinic or pharmacy
records.
Methods
Overall Study Design
We conducted field studies in Ethiopia, Kenya, Rwanda,
and Uganda between October 2006 and June 2007 to
evaluate the feasibility and the reliability of collecting
data from patient interviews and medical and pharmacy
records to apply to a set of draft adherence indicators
for assessing adherence to ART in resource-limited
settings.
Facility Sample
In each country, the sample included 20 health facilities
offering different levels of care. Eligible HIV/AIDS treat-
ment facilities were required to have had at least 100
patients receiving ARVs a year before the study. We
first stratified all such facilities in each country by
region, and then chose study facilities randomly, exclud-
ing facilities that were too difficult to reach or that were
the focus of other adherence-related initiatives.
Data Collection
Trained data collectors interviewed patients exiting the
facility, examined a randomly selected sample of patient
records, and interviewed facility staff. Each data collec-
tion team included one team leader and three or four
data collectors. Data collectors were practicing pharma-
cists or physicians or senior-level students. The process
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lecting the data in each facility.
Patient exit interviews
We sought to interview a purposive sample of 30
patients on ARVs as they exited from each facility fol-
lowing their clinic visits on the day of data collection.
Data collectors first asked patients for consent and then
asked them a standard question about treatment adher-
ence over the previous three days. They also collected
information on factors potentially affecting adherence,
such as the time spent getting to clinic, time spent wait-
ing in the clinic, and whether patients knew how to take
their medicines correctly.
Retrospective sample of patient records
In each facility in Kenya and Rwanda, data collectors
examined 100 randomly chosen pharmacy records from
patients who had attended the clinic 13 months (Kenya)
or 7 months (Rwanda) before the survey, and abstracted
days of medicine each patient had been dispensed over
the succeeding 12 or 6 months, respectively. In a second
sample of 100 records of patients who attended the clinic
4 months prior to the day of data collection, dates of
their next clinic appointment were abstracted. Data col-
lectors abstracted pill count and self-reported adherence
data from all records where available. Following a review
of the experience in the first two surveys, data collectors
in Uganda and Ethiopia abstracted records of a single
cohort of 100 randomly selected patients in each facility
who had attended the clinic 7 months before.
Additional information extracted from clinic records
included demographic (age, gender) and clinical data
(World Health Organization [WHO] stage at initiation,
length of time on ARV therapy, and CD4 and viral load
test dates and results, where available).
Data Analysis
We entered all data into formatted Microsoft® Office
Excel 2003 spreadsheets and calculated the percentages
and means for each indicator for all patients and for
each facility, as appropriate. For each country, for each
facility, we calculated the summary statistics for all
patients sampled. Within country we took the median
facility indicator values, as well as the maximum, 75
th
percentile, 25
th percentile, and minimum. Using facility
median values helped prevent skewing the summary
results with outlying values, since our dual purpose was
to identify individual problem facilities and to assess
overall performance across facilities. For the dispensing-
based indicators, we examined results for the entire
sample, including patients who were lost to follow up
during the observation period. The data were then
entered into the Statistical Analysis System (SAS)® 9.1.3
and we calculated Pearson correlation coefficients
between all facility-level summary indicators.
When the four pilot surveys were completed, we
revised the methodology based on the overall quality of
the data that facilities routinely maintain in medical and
pharmacy records, the difficulty of collecting the data,
the observed results, correlations among the facility-
level summary indicators, and utility of the resulting
information. We simplified the methodology to focus on
five core adherence and attendance indicators. These
five indicators were validated in a later study by com-
paring them to changes in clinical outcomes observed in
patients newly initiating treatment; the results are
reported in a companion paper [25].
Ethics committee approval
In three of the countries the national AIDS control pro-
gram gave permission to conduct the surveys and colla-
borated in the study as part of their quality
improvement processes. In Ethiopia this approval was
given by the Drug Administration and Control Author-
ity (DACA). All patients interviewed gave verbal consent
a n dw e r ef r e et os t o pt h ei n t e r v i e wa ta n yt i m e .P a t i e n t
and staff interviews were conducted privately and all
results were reported anonymously.
Results
Characteristics of Health Facilities and Patients
Characteristics of the facilities included in the sample
can be seen in Table 1. Overall, we collected data from
medical and pharmacy records in 78 of 80 targeted
health facilities. A number of facilities did not have the
target number of 30 patients attending on the day of
data collection, so we interviewed a median of 21 per
facility. In Ethiopia and Uganda, the median number of
records examined was 100. With two samples of records
in Kenya and Rwanda, the median numbers of recent (4
months before data collection) and long-term (7 or 13
months before data collection) patient records examined
were 70 and 59 respectively.
Problems in data collection
Although most data were available in the sample facil-
ities, challenges in collecting data are outlined below.
Patient exit interviews
Interviewers targeted patients on ARVs except those
starting ARVs on the day of the survey. In all cases the
interviews were voluntary and very few patients refused.
However, in some facilities, few patients attended on the
day of the survey.
Sampling patient records
Sample patient records were usually identified by linking
data from the attendance register for patients on ART
in a given prior month with clinical and pharmacy
records. In some cases, the attendance register did not
distinguish between those on ART and those not on
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the most feasible manner from the ART Initiation Regis-
ter, from sequentially numbered clinic or pharmacy
records, or from a list of all patients currently in
treatment.
Days of medicine dispensed
In most cases, it was feasible to determine the number
of days of medicines dispensed over the previous six
months. However, in four facilities there were no dis-
pensing records and the facility did not regularly pre-
scribe the same number of days of medicine, so this
indicator was not possible to measure.
Self-Reported Adherence in Exit Interviews
Ninety four percent of all patients reported perfect
adherence. When analyzed by country, the percentage
varied from 91% in Rwanda to 96% in Kenya and Ethio-
pia (Table 2), and when analyzed by facility, the median
facility-specific percentage of patients with 100% self-
reported adherence in the previous three days was 100%
in Rwanda and 96.7% in the other three countries. How-
ever, there were facilities in which the percentage of
patients with self-reported perfect adherence was as low
as 60%. The overall mean percentage of doses patients
reported taking across facilities was 99.4% or above;
however, the facility mean was as low as 85%. (Figure 1
and Table 3).
Dispensing-Based Adherence Measures from Patient
Records
Analyses of retrospective dispensing records for 5,890
patients under treatment showed that the percentage of
Table 1 Characteristics of health facilities and patients included in the sample
Kenya Rwanda Uganda Ethiopia TOTAL
Facility Characteristics
# facilities 20 (19) * 20 (18,17)** 19 20 79
Teaching/Referral Hospital 7 2 5 11 25
District Hospital 6 14 7 9 36
Faith-based Hospital 5 0 3 0 8
Health Center/Clinic 1 4 2 0 7
Other Hospital 1 0 2 0 3
Median of facility mean
# of patients/week
(facility minimum - maximum)
230 (48-1,525) 150 (30-750) 120 (31-2,045) 205 (40-750) 176 (30-2,045)
# of patients/hour/clinician
(facility minimum - maximum)
2.2 (0.6-20) 1.9 (0.4-7.5) 2.0 (0.3-8.3) 2.0 (0.4-4.4) 2.0 (0.3-20)
Patient Exit Interviews
# interviews 373 285 408 565 1,631
Age (years) 37.1 36.2 38.7 33.3 36.3
Percent female
(facility minimum - maximum)
68 (38-77) 62 (47-73) 68 (46-74) 55 (14-70) 63
(14-77)
Months on treatment
(facility minimum - maximum)
11
(5-34)
13
(8-27)
15
(5-27)
13
(7-20)
13
(5-34)
Record Reviews
Total # of records examined 1998 2609*** 1693 1982 8282
# records 13 months post ART initiation 930 1255 –––
# records 4 months post ART initiation 1060 1354 –––
Age (years)
(facility minimum - maximum)
37 (8-43) 37 (34-40) 37 (35-41) 33 (31-38) 36 (8-43)
Percent female
(facility minimum - maximum)
68 (38-77) 62 (47-73) 68 (46-74) 55 (14-70) 63 (14-77)
Months on treatment
(facility minimum - maximum)
10 (3-14) 13 (8-22) 10 (4-17) 6 (2-8) 10 (2-22)
% Patients with WHO Stage 3 or 4 at ART initiation –– 79 83 81
* 20 facilities for pharmacy records, 19 for attendance and exit interviews
** 20 facilities for attendance, 18 for exit interviews, and 17 for dispensing records
*** 1255 records counted for attendance and 1279 counted for dispensing, 1154 for gap of 30 days or more in dispensing
–data not collected
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months was high at 91% (95% confidence intervals (CI):
91% to 92%) with 13.7% (CI: 13%-15%) of patients having
a gap of 30 days or more in dispensed medicine (Table 2).
The median facility in each country achieved a rate of
days covered by dispensed medicine of 90% or above,
with 2%-19% of patients experiencing a gap of 30 days
or more in their medication coverage. However, the
mean coverage in some individual facilities was less than
80% with as many as 42% of patients experiencing a gap
of 30 days or more (Figure 2 and Table 3).
The recommended target threshold for adherence in
many programs is 95%. Although the average percentage
of days covered by medicine dispensed was high, fewer
health facilities were able to maintain patients at this
target level over the 6, or 12 month study periods.
Figure 1 Distribution of facility-level percentage of self-reported full adherence by country. Note: Horizontal line represents the value of
the outcome in the median facility in each country; box covers the values from the 25
th to 75
th percentile of facilities; diamonds represent
values in individual facilities that lie above the 75
th percentile or below the 25
th percentile.
Table 2 Patient indicators of adherence and clinic attendance across health facilities in four countries based on exit
interviews and record review
Kenya Rwanda Uganda Ethiopia TOTAL
# patients interviewed 373 285 408 565 1631
% with self reported full adherence (+/- 1.96*SE) 96.0 (2.0) 90.9 (3.3) 92.2 (2.6) 96.3 (1.6) 94.2 (1.1)
# records counted for dispensed medicine 936 1279 1693 1982 5890
Percentage of days covered (+/- 1.96*SE) 81.6 (1.7) 95.1 (0.5) 81.8 (0.7) 93.0 (0.6) 91.1 (0.4)
# records counted for gap in medicine 936 1154 1693 1982 5765
% patients with gap of 30 days or more (+/- 1.96*SE) 25.1 (2.8) 4.0 (1.1) 18.1 (1.8) 10.2 (1.3) 13.7 (0.9)
# records checked for attending next appointment 1998 2609 1693 1982 8282
% attended on or before next appointment
(+/- 1.96*SE)
78.3 (1.8) 78.4 (1.6) 71.7 (2.2) 73.5 (1.9) 75.8 (0.9)
% attended within 3 days of appointment (+/- 1.96*SE) – 93.4 (1.0) 76.3 (2.0) 87.9 (0.1) 87.1 (0.7)
% attended within 30 days of appointment
(+/- 1.96*SE)
96.3 (0.8)* 97.8 (0.6) 86.7 (1.6) 94.6 (1.0) 94.4 (0.5)
– Data not collected
* Within 60 days of appointment
Chalker et al. BMC Health Services Research 2010, 10:43
http://www.biomedcentral.com/1472-6963/10/43
Page 5 of 11Table 3 Facility-level indicators of adherence and clinic attendance across health facilities in four countries based on
exit interviews and record review
Median facility percentages
(minimum, 25
th percentile, 75
th percentile, maximum value)
Indicator and Data Source Kenya Rwanda Uganda Ethiopia
Self-report from exit interview (19 facilities/373
patients)
(18 facilities/285
patients)
(19 facilities/408
patients)
(20 facilities/565
patients)
Perfect self-reported adherence in last 3 days 96.7
(80,95,100,100)
100
(60,84,100,100)
96.7
(63,91,100,100)
96.7
(90,93,100,100)
Mean self-reported adherence over past 3 days 99.4
(89,98,100,100)
100
(88,95,100,100)
99.4
(85,98,100,100)
99.6
(96,99,100,100)
Days covered by dispensed medicine from records (20 facilities/936
records)
(17 facilities/1279
records)
(19 facilities/1693
records)
(20 facilities/1982
records)
Mean % of days covered by medicine dispensed 90
(25,82,95,100)
95
(88,93,97,99)
91
(76,86,92,97)
93
(82,92,95,99)
% of patients with ≥ 95% days covered by medicine
dispensed
63
(12,58,79,100)
80
(54,63,87,99)
52
(20,46,69,81)
76
(55,69,82,94)
% of patients with ≥ 30 days gap in medicines
dispensed
15
(0,7,30,41)
2
(0,1,6,12)
19
(0,12,24,42)
9
(0,5,13,33)
Patient attendance at clinic from records (19 facilities/1060
records)
(20 facilities/1354
records)
(19 facilities/1690
records)
(20 facilities/1982
records)
On or before day of appointment 84
(25,77,92,100)
91
(14,79,95,98)
79
(15,66,87,100)
72
(58,64,79,99)
Within three days of appointment – 96
(67,93,97,100)
80
(20,75,91,100)
87
(72,84,93,99)
Within thirty days of appointment 98*
(52,96,100,100)
99
(96,97,100,100)
95
(29,88,97,100)
99
(87,94,100,100)
– Data not collected
* Within 60 days of appointment
Figure 2 Distribution of facility-level mean percentage of days covered by dispensed drugs in last 6 months by country.N o t e :
Horizontal line represents the value of the outcome in the median facility in each country; box covers the values from the 25
th to 75
th
percentile of facilities; diamonds represent values in individual facilities that lie above the 75
th percentile or below the 25
th percentile.
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performance in achieving the 95% coverage target ran-
ged from 52%-80% of patients (Table 3). In individual
facilities, the percentage of patients who achieved at
least 95% dispensing coverage varied from 12%-100%.
Clinic Attendance from Clinic Records
The clinic attendance measurement was lower and more
variable than the medication coverage measurement.
Overall, 76% (CI: 75%-77%) of patients attended their
appointment on or before the scheduled day; 87% (CI:
86%-88%) attended within 3 days; and 94% (CI: 94%-
95%) attended within 30 days (Table 2). Across coun-
tries, the median facility had from 72%-91% of patients
attending their next appointment on or before the day
scheduled and from 80%-96% attending within 3 days of
their appointments (Table 3). Variability across indivi-
dual facilities was larger, with only 14% of patients
attending on time in one facility and 20% attending
within 3 days in another facility (Figure 3).
Pill Counts and Self-Reports in Clinic Notes
Overall, only 15% of patient records we examined
included a pill count and 45% included a self-reported
adherence measure; therefore, we excluded these
measures.
Correlations between Indicators
The correlations between the facility-level indicators are
presented in Table 4. The correlations between the dis-
pensing-based indicators and the other adherence indi-
cators did not differ for the entire sample of patients
(indicators 8-10 in Table 4), or for only those still in
t r e a t m e n ta tt h ee n do ft h eo b s e r v a t i o np e r i o d( i n d i c a -
tors 1-3). As a result we used the data from the entire
sample.
The percentages of days covered by dispensed medi-
cine and of patients with more than 95% of days cov-
ered both were significantly correlated with the
percentages who attended their appointments on time
(i.e., on or before the scheduled day of the appoint-
ment), within 3 days, and within 30 days of their
appointment, but were not correlated with self-reported
adherence either in the clinical notes or in exit inter-
views. However, self-reported adherence at exit inter-
view was significantly correlated with the percentage of
patients who attended within 3 days of their appoint-
ment, and the percentage with perfect self-reported
Figure 3 Distribution of facility-level values for patient attendance to next appointment. Note: Horizontal line represents the value of the
outcome in the median facility in each country; box covers the values from the 25
th to 75
th percentile of facilities; diamonds represent values in
individual facilities that lie above the 75
th percentile or below the 25
th percentile.
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Indicators: 2 3 4 5 6 7 8 9 10 11 12 13
1 0.88753 -0.4332 0.19847 0.60229 0.24169 0.08673 0.78536 0.46213 -0.27041 0.02056 0.07059 -0.00039
<.0001 0.0001 0.0971 <.0001 0.0438 0.5946 <.0001 <.0001 0.0207 0.8629 0.5825 0.9976
39 74 71 55 70 40 72 71 73 73 63 63
2 1 -0.84969 0.33361 0.59568 0.50325 0.48017 0.77531 0.96964 -0.73886 0.48363 0.29674 0.24588
<.0001 0.0379 <.0001 0.0013 0.0097 <.0001 <.0001 <.0001 0.0018 0.0745 0.1424
39 39 39 39 38 28 39 39 39 39 37 37
3 1 -0.4246 -0.75195 -0.49922 -0.05321 -0.4183 -0.7567 0.89989 -0.21967 -0.1382 -0.059
0.0002 <.0001 <.0001 0.7443 0.0003 <.0001 <.0001 0.06 0.2801 0.646
75 71 55 70 40 72 71 73 74 63 63
4 1 0.74158 0.61924 -0.08272 0.41409 0.28721 -0.41749 0.19 0.14293 0.09498
<.0001 <.0001 0.6071 0.0003 0.0159 0.0003 0.1125 0.2718 0.4665
73 56 72 41 71 70 72 71 61 61
5 1 0.86842 0.16057 0.6507 0.61115 -0.71072 0.27723 0.37337 0.28431
<.0001 0.38 <.0001 <.0001 <.0001 0.0404 0.009 0.0502
56 55 32 56 56 56 55 48 48
6 1 -0.02434 0.32879 0.48872 -0.48896 0.26292 0.4468 0.30016
0.88 0.0055 <.0001 <.0001 0.0279 0.0003 0.0188
72 41 70 69 71 70 61 61
7 1 0.16434 0.36403 -0.0598 0.08467 0.02428 0.01863
0.3174 0.0247 0.714 0.6083 0.885 0.9116
42 39 38 40 39 38 38
8 1 0.42663 -0.56325 0.37349 -0.08788 -0.06737
0.0002 <.0001 0.0012 0.497 0.6029
73 72 73 72 62 62
9 1 -0.74195 0.4772 0.18678 0.16058
<.0001 <.0001 0.146 0.2125
72 72 71 62 62
10 1 -0.40181 -0.08735 -0.06228
0.0004 0.496 0.6277
74 73 63 63
11 1 0.26338 0.25041
0.0386 0.0496
74 62 62
12 1 0.92186
<.0001
66 66
Key: In each cell
Pearson Correlation Coefficients: Bold correlations = p < 0.05
Prob > |r| under H0: Rho = 0
Number of Observations
Indicators
1. % days covered by dispensed medicine if still in treatment
2. % patients with 95% days covered by dispensed medicine if still in treatment
3. % patients with gap of 30 days or more in dispensed medicine if still in treatment
4. % patients who attended on or before their appointment
5. % patients who attended within 3 days of their appointment
6. % patients who attended within 30 days of their appointment
7. From records: % Self reported good adherence
8. % days covered by dispensed medicine
9. % patients with 95% days covered by dispensed medicine
10. % patients with gap of 30 days or more in dispensed medicine
11. % patients remaining in treatment
12. From exit interview: % full adherence
13. From exit interview: average % adherence
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tors than the average self-reported adherence. The indi-
cator for attending appointments within 3 days had
higher correlations with all indicators than the indicator
for attending on or before the scheduled day of the
appointment.
Discussion
We have shown, using routine data sources, that it is
possible to use standardized methods to collect data and
to measure important aspects of patient treatment
adherence and clinic attendance in a wide variety of
health facilities in resource-poor settings and that the
different facility-level summary indicator results are cor-
related. Because taking medicine is a private affair, all
individual-level adherence measurements are indirect.
Aggregated at the facility level, summary results for dif-
ferent indicators can point to interventions in different
systems to improve facility performance.
In the four survey countries, facilities generally main-
tained patients at a high level of treatment adherence;
however, for all indicators, we identified some facilities
that performed less well, which provided a target for
quality improvement efforts. The measurement
approaches offer a systematic way to assess and compare
adherence measures across facilities and programs and
to assess the impact of system-level interventions to
improve adherence.
Measuring patient self-report about recent patterns of
adherence is a low cost and commonly used method to
assess adherence, which has correlated with clinical out-
comes both in a meta-analysis [9] and in several
resource-poor settings [8,10,21,21,27], although it has
been assessed in various ways [28]. For purposes of a
cross-sectional survey, exit interviews provide an oppor-
tunity to standardize the self-report question (i.e., num-
ber of doses missed in the last three days; achievement
of 100% adherence). In the current field studies, a small
percentage of clinical records included self-reported
adherence and pill counts. In addition, the self-reporting
measurement in clinic records suffers from inconsistent
questioning and irregular recording. Standardizing the
questions and the recording methods allow for a useful
comparison. Because self-report measures tend to over-
estimate true adherence compared to more objective
measures [11,12], and the median levels reported in
these surveys are over 95%, this may not be a sensitive
enough measure to evaluate interventions to improve
adherence.
Facilities with electronic pharmacy records often use
dispensing data to calculate adherence to therapy [15].
Several studies in industrialized countries have shown
associations between pharmacy-based ARV adherence
measures and clinical outcomes, including viral load and
CD4 counts [17,29]. These methods have also been
shown to be feasible and valid in an African setting
using electronic data [13]. However, using dispensing
records to measure adherence in settings with manual
record systems has not been widely tested. We have
demonstrated that such data are possible to gather in
resource-poor settings in East Africa.
The average percentage of days covered by ARV ther-
apy dispensed over six months provides a useful patient
population-based measure of intermediate-term adher-
ence. Similarly, the percentage of patients who experi-
ence a 30-day gap in treatment measures the ability of
health facilities to retain patients in consistent therapy.
T h e s em e a s u r e sc a nh e l pap r o g r a mm a n a g e ri d e n t i f y
facilities with low levels of dispensing coverage or
patient retention. Different factors can contribute to low
dispensing coverage and patient retention, including
poor drug supply and inadequate dispensing and patient
counselling practices, which can be addressed at the sys-
tem level.
Patients need to attend appointments consistently to
manage many clinical issues that may arise during ARV
treatment and to avoid gaps in therapy. Missed appoint-
ments correlate with other aspects of non-adherence in
our data and elsewhere [15,21,30,31]. Because patients
often receive a 30-day supply of medicines and a follow-
up appointment after 28 days, they will not miss taking
their medicine, even if they do not come on their sched-
uled appointment date. We therefore propose atten-
dance within three days of a scheduled appointment as
a key adherence measure. Not all treatment programs in
Africa have easy access to information on who is
expected to attend on a given day and who has not
appeared for their appointment. A standard approach
for identifying patients that miss appointments could
help programs develop effective community outreach
systems; in addition, information on the percentage of
patients missing appointments would allow a program
manager to target poorly performing facilities and to
identify causes and appropriate interventions.
Deciding to take steps to improve adherence levels
depends on available human and financial resources. One
method of deciding which facilities need to improve is to
set target levels for each of the main indicators. The cur-
rent results could serve as benchmarks for future surveys
in other locations. Another method would be to look at
the mean scores achieved by most facilities and target the
poorest performing 5%, 10%, or 25% for interventions.
For example, across facilities, a median of 97% of patients
reported full adherence. However, in the bottom 25% of
facilities, the measure was 93% or less. In the bottom
10% of facilities, 84% or less of patients reported full
adherence, and in the bottom 5% of facilities, the figure
fell to 78% or less (Table 5).
Chalker et al. BMC Health Services Research 2010, 10:43
http://www.biomedcentral.com/1472-6963/10/43
Page 9 of 11Encouragingly, most facilities surveyed are maintaining
high rates of patient adherence and attendance. However,
all countries have facilities with low measures that need
systems strengthening. Using simple, low-cost methods
to identify poorly performing facilities would allow ART
program managers to examine the causes of poor perfor-
mance and work with facilities to make improvements.
This standardized methodology and associated indicators
can also be adapted to become part of an ongoing moni-
toring system. A manual on how to conduct the adher-
ence assessments and spreadsheets for processing the
data are available on request from the first author.
Our study made no assessment of patient retention as
this was not part of our objectives. We recognize the
importance of the assessment of retention. Retention
data are already collected by many agencies. Our work
reported here is to explore the feasibility of assessing
the performance of health facilities in supporting adher-
ence among their patients. The method of selecting
patient records was to identify patients who had
attended the facility 7 or 13 months before the month
of the survey. To do this, the records had to be accessi-
ble in the facility. There was an implicit bias towards
patients who keep appointments and those whose
records were available at the facility; thus, the indicators
m a yr e f l e c tt h ee x p e r i e n c eo f patients still in treatment
who maintain better adherence.
Evaluating and monitoring adherence to ARV treat-
ment are critical to using health care resources effec-
tively and efficiently, reducing rates of drug resistance to
first-line therapies, and improving patient outcomes.
The four field tests provide strong evidence that adher-
ence evaluation is possible using routine data that can
be collected systematically from a wide range of health
facilities in resource-poor settings. The challenge now
will be to introduce monitoring of these indicators on a
routine basis and using them as the basis for facility-
level quality improvement efforts.
Conclusions
The four field tests have shown that data to measure
indicators of adherence based on days covered by
dispensed medicine, attendance at appointments and
self report can be collected systematically from health
facilities in a wide variety of resource-poor settings and
that the indicators correlate with each other. These
methods allow comparison of the performance of pro-
grams and facilities between each other, over time, and
to evaluate the success of interventions.
Most facilities surveyed are maintaining high rates of
patient adherence and attendance. However, all coun-
tries have facilities with low measures that need systems
strengthening. Using these simple, low-cost methods to
identify poorly performing facilities enables ART pro-
gram managers to examine the causes of poor perfor-
mance and work with facilities to make improvements.
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